Pharmacy Benefit Managers Challenge Trump's Drug Price Transparency Proposal
Pharmacy benefit managers (PBMs) are opposing a significant proposal aimed at increasing transparency in drug pricing, claiming it may be illegal.
Pharmacy benefit managers (PBMs) are opposing a significant proposal aimed at increasing transparency in drug pricing, claiming it may be illegal.
The American Association of Cancer Researchers' annual meeting showcases significant advancements in the development of KRAS-targeting therapies, particularly by Revolution Medicines.
Early retirement at 62 can be appealing, but it comes with significant financial considerations, including a $47,000 healthcare gap before Medicare starts.
Zai Lab and Amgen have announced a partnership to evaluate a new approach to lung cancer treatment, marking a significant step in cancer research.
The FDA has accepted Ultragenyx's Biologics License Application for its gene therapy UX111, aimed at treating Sanfilippo Syndrome.
Despite a notable increase in Medicare Advantage spending in Puerto Rico, the expected improvements in plan quality have not materialized.
The latest issue of Health Affairs delves into critical topics such as drug pricing strategies, the role of behavioral health, and hospital policies.
The first year of the ACO program aimed at enhancing equity and community health has shown promising results, according to Health Affairs.
A recent analysis explores how changing patient cost-sharing practices are affecting the financial stability of both urban and rural hospitals.
A recent study highlights a notable decline in hospital utilization in Maryland, showing an 11 percentage point decrease compared to other states from 2013 to 2023.
A recent analysis highlights the trends in national spending on mental health and substance use disorder treatment from 2000 to 2021, reflecting case growth over the years.
The pancreatic cancer drug Daraxonrasib from Revolution Medicines is reportedly achieving remarkable results, with some patients experiencing doubled survival times.
In a recent directive, Trump has called on federal agencies to expedite access to psychedelic treatments and reconsider their classification as controlled substances.
The podcast 'Why Should I Trust You?' emphasizes the need for communication between MAHA and public health, highlighting the stakes involved.
While there is a sense of optimism regarding Trump's choice for the CDC, employees express a cautious outlook, especially concerning RFK Jr.'s involvement.
A recent analysis reveals trends in employer-based health insurance, affecting 165.6 million individuals under 65 years old as of March 2025.
In a recent update, Truist has adjusted its outlook for Community Health Systems, Inc. as part of a broader review of the healthcare sector.
Recent headlines may suggest a growing skepticism towards vaccines among Americans, but a new poll indicates that this perception may not reflect reality.
As cyberattacks on health care systems escalate, the potential for patient harm grows. Andrea Downing highlights the urgent need for improved defenses against these threats.
Recent updates on MAHA highlight a significant breakthrough in Duchenne muscular dystrophy, alongside ongoing challenges in cancer treatment and other health developments.